Related Experiment Videos
Treatment strategies for Aspergillus infections
Tom M. Chiller1, David A. Stevens
1Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA
Abstract:
Infections caused by Aspergillus species consist of many different disease presentations, ranging from relatively benign asthma in atopic disease to life-threatening systemic invasive infections. The spectrum of disease manifestations is determined by a combination of genetic predisposition, host immune system defects, and virulence of the Aspergillus species. For the purposes of this discussion, we will address three principal entities: invasive aspergillosis, both primary and disseminated, pulmonary aspergilloma, and allergic bronchopulmonary aspergillosis. Amphotericin B is the standard of treatment for severe Aspergillus infections, despite the fact that mortality in these patients remains high. Alternative therapies such as combination regimens and itraconazole also have efficacy against Aspergillus infections. We discuss the role of current therapies, the potential role of drugs in development, and the results of ongoing research with combination and immunotherapies. Copyright 2000 Harcourt Publishers Ltd.
Insights
Aspergillus infections range from asthma to life-threatening invasive disease. Current treatments like Amphotericin B have limitations, prompting research into combination therapies and immunotherapies for better outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Immunology
Background:
- Aspergillus species cause a spectrum of diseases, from allergic conditions to severe invasive infections.
- Disease severity depends on host genetics, immune status, and fungal virulence.
- Key conditions include invasive aspergillosis, pulmonary aspergilloma, and allergic bronchopulmonary aspergillosis.
Purpose of the Study:
- To review current therapeutic strategies for Aspergillus infections.
- To explore emerging treatments, including combination regimens and immunotherapies.
- To discuss ongoing research and future directions in managing these infections.
Main Methods:
- Literature review of established and experimental therapies for Aspergillus infections.
- Analysis of treatment efficacy and outcomes for invasive aspergillosis, aspergilloma, and allergic bronchopulmonary aspergillosis.
- Discussion of drug development pipelines and immunotherapy research.
Main Results:
- Amphotericin B remains a standard treatment for severe Aspergillus infections, but high mortality persists.
- Alternative therapies, including itraconazole and combination regimens, show efficacy.
- Ongoing research focuses on novel drug combinations and immunotherapies to improve patient outcomes.
Conclusions:
- Despite existing treatments, severe Aspergillus infections carry a significant mortality risk.
- Further research into combination therapies and immunotherapies is crucial for advancing treatment paradigms.
- Developing new therapeutic strategies is essential to combat the challenges posed by Aspergillus infections.